Can-Fite BioPharma Ltd. (CANF)
USD 1.33
(-6.34%)
USD 1.33
(-6.34%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -8.18 Million USD | 18.98% |
| 2022 | -10.08 Million USD | 21.38% |
| 2021 | -12.82 Million USD | 8.97% |
| 2020 | -14.12 Million USD | -18.13% |
| 2019 | -11.99 Million USD | -122.67% |
| 2018 | -6.53 Million USD | -22.32% |
| 2017 | -6.35 Million USD | 36.89% |
| 2016 | -8.67 Million USD | -55.08% |
| 2015 | -5.04 Million USD | 28.5% |
| 2014 | -6.81 Million USD | 28.91% |
| 2013 | -8.51 Million USD | -50.99% |
| 2012 | -5.65 Million USD | -234.6% |
| 2011 | -7.83 Million USD | 50.52% |
| 2010 | -3.35 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.04 Million USD | 0.0% |
| 2024 Q1 | -2.04 Million USD | -11.82% |
| 2023 Q4 | -1.83 Million USD | 1.66% |
| 2023 Q2 | -1.78 Million USD | 34.22% |
| 2023 FY | - USD | 18.98% |
| 2023 Q1 | -2.71 Million USD | 12.03% |
| 2023 Q3 | -1.86 Million USD | -4.54% |
| 2022 Q4 | -3.08 Million USD | -19.82% |
| 2022 Q1 | -2.37 Million USD | 41.16% |
| 2022 Q2 | -2.07 Million USD | 12.66% |
| 2022 Q3 | -2.57 Million USD | -24.3% |
| 2022 FY | - USD | 21.38% |
| 2021 Q4 | -4.02 Million USD | -14.76% |
| 2021 FY | - USD | 8.97% |
| 2021 Q1 | -2.17 Million USD | 37.86% |
| 2021 Q2 | -3.13 Million USD | -44.31% |
| 2021 Q3 | -3.51 Million USD | -12.03% |
| 2020 Q3 | -2.47 Million USD | 35.29% |
| 2020 Q4 | -3.49 Million USD | -40.94% |
| 2020 Q1 | -4.27 Million USD | -135.07% |
| 2020 FY | - USD | -18.13% |
| 2020 Q2 | -3.83 Million USD | 10.41% |
| 2019 Q1 | -1.7 Million USD | 50.32% |
| 2019 FY | - USD | -122.67% |
| 2019 Q4 | -1.81 Million USD | 34.19% |
| 2019 Q2 | -2.86 Million USD | -68.45% |
| 2019 Q3 | -2.76 Million USD | 3.59% |
| 2018 Q4 | -3.42 Million USD | -3506.32% |
| 2018 FY | - USD | -22.32% |
| 2018 Q2 | -1.03 Million USD | 34.45% |
| 2018 Q3 | -95 Thousand USD | 90.84% |
| 2018 Q1 | -1.58 Million USD | 64.88% |
| 2017 Q2 | -1.82 Million USD | -298.69% |
| 2017 Q3 | -583.89 Thousand USD | 68.07% |
| 2017 Q1 | -458.69 Thousand USD | 78.48% |
| 2017 Q4 | -4.5 Million USD | -671.43% |
| 2017 FY | - USD | 36.89% |
| 2016 Q2 | -1.64 Million USD | -42.92% |
| 2016 FY | - USD | -55.08% |
| 2016 Q3 | -2.03 Million USD | -24.06% |
| 2016 Q4 | -2.13 Million USD | -4.49% |
| 2016 Q1 | -1.15 Million USD | -126.05% |
| 2015 Q2 | -1.54 Million USD | -310.97% |
| 2015 Q4 | -508.88 Thousand USD | 75.36% |
| 2015 Q3 | -2.06 Million USD | -33.62% |
| 2015 FY | - USD | 28.5% |
| 2015 Q1 | -376.06 Thousand USD | 79.5% |
| 2014 Q2 | -1.58 Million USD | 10.82% |
| 2014 Q3 | -1.07 Million USD | 32.64% |
| 2014 FY | - USD | 28.91% |
| 2014 Q1 | -1.78 Million USD | 48.21% |
| 2014 Q4 | -1.83 Million USD | -71.29% |
| 2013 Q2 | -1.71 Million USD | 0.26% |
| 2013 Q4 | -3.44 Million USD | -138.59% |
| 2013 Q3 | -1.44 Million USD | 15.85% |
| 2013 Q1 | -1.71 Million USD | 10.8% |
| 2013 FY | - USD | -50.99% |
| 2012 Q2 | -1.18 Million USD | 17.31% |
| 2012 Q1 | -1.43 Million USD | -22.45% |
| 2012 Q4 | -1.92 Million USD | -61.08% |
| 2012 Q3 | -1.19 Million USD | -0.91% |
| 2012 FY | - USD | -234.6% |
| 2011 Q2 | -1.19 Million USD | 13.38% |
| 2011 Q4 | -1.17 Million USD | -12.64% |
| 2011 Q3 | -1.03 Million USD | 12.81% |
| 2011 FY | - USD | 50.52% |
| 2011 Q1 | -1.37 Million USD | -46.36% |
| 2010 Q3 | -872.67 Thousand USD | 0.0% |
| 2010 Q4 | -940.4 Thousand USD | -7.76% |
| 2010 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.67 Million USD | 74.178% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Armata Pharmaceuticals, Inc. | -39.91 Million USD | 79.508% |
| Actinium Pharmaceuticals, Inc. | -51.13 Million USD | 84.002% |
| Azitra, Inc. | -10.67 Million USD | 23.359% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -19.202% |
| Calidi Biotherapeutics, Inc. | -28.6 Million USD | 71.399% |
| CEL-SCI Corporation | -27.56 Million USD | 70.32% |
| iBio, Inc. | -14.02 Million USD | 41.659% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 66.927% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | 59.47% |
| Matinas BioPharma Holdings, Inc. | -22.82 Million USD | 64.162% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | 41.045% |
| NovaBay Pharmaceuticals, Inc. | -4.8 Million USD | -70.417% |
| NanoViricides, Inc. | -7.75 Million USD | -5.452% |
| Oragenics, Inc. | -20.87 Million USD | 60.819% |
| BiomX Inc. | -22.81 Million USD | 64.146% |
| BiomX Inc. | -22.81 Million USD | 64.146% |
| Protalix BioTherapeutics, Inc. | 11.65 Million USD | 170.209% |
| Palatin Technologies, Inc. | -29.03 Million USD | 71.823% |
| Scorpius Holdings, Inc. | -35.08 Million USD | 76.684% |